Article
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2019
Lee B, Lipton L, Cohen J, Tie J, Javed A A, Li L, Goldstein D, Burge M, Cooray P, Nagrial A, Tebbutt N C, Thomson B, Nikfarjam M, Harris M, Haydon A, Lawrence B, Tai D W M, Simons K, Lennon A M, Wolfgang C L, Tomasetti C, Papadopoulos N, Kinzler K W, Vogelstein B, Gibbs P
Abstract excerpt
BACKGROUND: In early-stage pancreatic cancer, there are currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumor DNA (ctDNA) analysis to inform adjuvant therapy decision making. MATERIALS AND METHODS: Patients considered by the multidisciplinary team to have resectable pancreatic adenocarcinoma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.